These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2226604)

  • 41. [Clinical study on the effects of chemotherapy as treatment of renal cell carcinoma].
    Onishi T; Iizuka N; Suzuki M; Mori Y; Kondo I; Nakada J; Masuda F; Machida T
    Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):43-9. PubMed ID: 3379331
    [No Abstract]   [Full Text] [Related]  

  • 42. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
    Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
    Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of vinblastine and doxorubicin in advanced renal cell carcinoma.
    Jekunen A; Stengård J; Pyrhönen S
    Eur J Cancer; 1994; 30A(2):245. PubMed ID: 8155397
    [No Abstract]   [Full Text] [Related]  

  • 45. Coumarin plus cimetidine: yet another angle for therapy of renal cell carcinoma.
    Kirkwood JM; Ernstoff MS
    J Clin Oncol; 1987 Jun; 5(6):836-7. PubMed ID: 3585440
    [No Abstract]   [Full Text] [Related]  

  • 46. [Radiotherapy in treatment of relapsing renal cell cancer].
    Metelev VV; Zharinov GM
    Vopr Onkol; 2008; 54(6):775-7. PubMed ID: 19241859
    [No Abstract]   [Full Text] [Related]  

  • 47. Retinoid-interferon therapy of solid tumors.
    Lippman SM; Lotan R; Schleuniger U
    Int J Cancer; 1997 Feb; 70(4):481-3. PubMed ID: 9033661
    [No Abstract]   [Full Text] [Related]  

  • 48. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 49. Interferon plus vinblastine in renal carcinoma patients who had failed on interferon alone.
    Merimsky O; Chaitchik S
    Eur J Cancer; 1990; 26(8):921. PubMed ID: 2145941
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of recurrent or metastatic renal cell carcinoma.
    Shah RN; Ahmad T; Eisen TG
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination therapy in kidney cancer: the next revolution?
    Buti S; Bersanelli M
    Lancet Oncol; 2015 Nov; 16(15):1441-1442. PubMed ID: 26482275
    [No Abstract]   [Full Text] [Related]  

  • 52. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
    Bukowski RM
    Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma.
    Geller JI; Dome JS
    Pediatr Blood Cancer; 2006 Apr; 46(4):527. PubMed ID: 16365852
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy of UFT for the treatment of renal cell carcinoma.
    Masuda F; Mori Y; Nakada J
    Prog Clin Biol Res; 1989; 303():707-9. PubMed ID: 2506559
    [No Abstract]   [Full Text] [Related]  

  • 55. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Becker A; Eichelberg C; Sun M
    Cancer; 2014 Jan; 120(1):7-10. PubMed ID: 24347382
    [No Abstract]   [Full Text] [Related]  

  • 56. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Halabi S; Rini BI; Escudier B; Stadler WM; Small EJ
    Cancer; 2015 Jun; 121(11):1906. PubMed ID: 25677867
    [No Abstract]   [Full Text] [Related]  

  • 57. Chest discomfort in a patient with cancer.
    Rabener MJ; Howell C
    JAAPA; 2015 Jun; 28(6):43-4, 466. PubMed ID: 25989434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Intraarterial chemotherapy for metastatic renal cell carcinomas: combination with MDR-overcoming agents].
    Kakehi Y; Yoshida O; Segawa T; Kanematsu A; Hiura M; Shichiri Y; Arai Y
    Hinyokika Kiyo; 1994 Oct; 40(10):925-9. PubMed ID: 7992710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
    Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
    Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled.
    Eisen T
    BJU Int; 2008 Dec; 102(11):1491-2. PubMed ID: 19007367
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.